ClinicalTrials.gg

Program

avatrombopag

Also written as “E5501”, “Avatrombopag” and “Avatrombopag 20 mg Oral Tablet”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic, led by 2 companies.

Furthest: phase 4, since Sep 13, 201125 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai180 open or runningphase 3since Sep 13, 2011Feb 27, 2007none ahead
Swedish Orphan Biovitrum71 open or runningphase 4since Nov 11, 2020Oct 27, 2017Jun 30, 2028phase 3 · NCT07786922

Also a collaborator on its studies: cmic-co-ltd-japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Feb 27, 2007.

  1. Sep 19, 2011Phase 1 study in Purpura, Thrombocytopenic, IdiopathicEisai · NCT01437384 · 36 enrolled · United States
  2. Dec 6, 2012Phase 1 study in Healthy VolunteersEisai · NCT01759394 · 36 enrolled · United States
  3. Jan 18, 2013Phase 1 study in HealthyEisai · NCT01774773 · 15 enrolled · Japan
  4. Oct 24, 20132 phase 3 studies in ThrombocytopeniaEisai · NCT01976104, NCT01972529
  5. Jan 13, 2014Phase 1 study in ThrombocytopeniaEisai · NCT02039076 · 48 enrolled · United States
  6. Aug 26, 2014Phase 2 study in ThrombocytopeniaEisai · NCT02227693 · 39 enrolled · Japan
  7. Jun 20, 2016Phase 1 study in Healthy ParticipantsEisai · NCT02809768 · 48 enrolled · United States
  8. Oct 27, 2017Swedish Orphan Biovitrum's first study: phase 3 study in ThrombocytopeniaNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT03326843 · 4 enrolled · United States
  9. Mar 7, 2018Phase 3 study in ThrombocytopeniaSwedish Orphan Biovitrum · NCT03471078 · 122 enrolled · United States, China, Hungary and more
  10. Aug 14, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT04516967 · 75 enrolled · United States, France, Germany and more
  11. Nov 11, 2020Phase 4 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT04638829 · 60 enrolled · United States
  12. Sep 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT05046327
  13. Apr 21, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicSwedish Orphan Biovitrum · NCT05369208 · 19 enrolled · Japan
  14. Jul 30, 2026Phase 3 study in Anemia, AplasticSwedish Orphan Biovitrum · NCT07786922 · 26 planned

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Anemia, AplasticSwedish Orphan Biovitrum · NCT07786922

TargetBeta

MPL →read by rule
“The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, ”NCIt, by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
romiplostimruleAmgenphase 438
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07786922Anemia, Aplastic3Not yet recruitingSwedish Orphan BiovitrumJun 30, 202826
NCT05369208Purpura, Thrombocytopenic, Idiopathic · Japan3CompletedSwedish Orphan BiovitrumJan 17, 202419
NCT05046327Purpura, Thrombocytopenic, Idiopathic3WithdrawnSwedish Orphan BiovitrumApr 6, 20240
NCT04638829Purpura, Thrombocytopenic, Idiopathic · United States4CompletedSwedish Orphan BiovitrumJan 3, 202460
NCT04516967Purpura, Thrombocytopenic, Idiopathic · United States, France, Germany and more3CompletedSwedish Orphan BiovitrumNov 8, 202375
NCT03471078Thrombocytopenia · United States, China, Hungary and more3CompletedSwedish Orphan BiovitrumAug 28, 2020122
NCT03326843Thrombocytopenia · United States3TerminatedSwedish Orphan BiovitrumFeb 25, 20194
NCT02809768Healthy Participants · United States1CompletedEisaiAug 201648
NCT02227693Thrombocytopenia · Japan2CompletedEisaiApr 1, 201539
NCT02039076Thrombocytopenia · United States1CompletedEisaiJun 201448
NCT01976104Thrombocytopenia · United States, Argentina, Australia and more3CompletedEisaiJan 30, 2017204
NCT01972529Thrombocytopenia · United States, Argentina, Australia and more3CompletedEisaiJan 26, 2017231
NCT01774773Healthy · Japan1CompletedEisaiJul 201315
NCT01759394Healthy Volunteers · United States1CompletedEisaiJan 201336
NCT01438840Purpura, Thrombocytopenic, Idiopathic · Australia, Belgium, Bulgaria and more3CompletedEisaiNov 201349
NCT01437384Purpura, Thrombocytopenic, Idiopathic · United States1CompletedEisaiMar 201236
NCT01433978Purpura, Thrombocytopenic, Idiopathic · United States3TerminatedEisaiSep 201324
NCT01355289Thrombocytopenia · United States2CompletedEisaiFeb 201465
NCT01327872Purpura, Thrombocytopenic, Idiopathic · Netherlands1CompletedEisaiApr 201184
NCT01289509Purpura, Thrombocytopenic, Idiopathic · United States1CompletedEisaiMar 201142
NCT01260155Healthy Subjects · United States1CompletedEisaiJun 201016
NCT01251731Healthy Subjects · United States1CompletedEisaiJan 201136
NCT00914927Thrombocytopenia · United States2CompletedEisaiNov 11, 2011130
NCT00625443Purpura, Thrombocytopenic, Idiopathic · United States2CompletedEisaiJun 200953
NCT00441090Purpura, Thrombocytopenic, Idiopathic · United States2CompletedEisaiJan 200964

How it is read

Names in the registry

  • “E5501”, 9 entries
  • “Avatrombopag”, 8 entries
  • “Avatrombopag 20 mg Oral Tablet”, 2 entries
  • “Avatrombopag Oral Tablet”, 2 entries
  • “avatrombopag”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.